Evidence map›Paper›PMID 41536555›Full record

ArticleLiver cancer2026

Change in Liver Function after Selective Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: JIVROSG-2001 PRESIDENT-ALBI - A Secondary Analysis of a Multicenter Randomized Controlled Trial.

Yoshihisa Kodama, Masafumi Ikeda, Yasuaki Arai, Yoshitaka Inaba, Toshihiro Tanaka, Yasunori Arai, Shunsuke Sugawara, Hajime Yamazaki, Takeshi Aramaki, Hiroshi Anai and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Liver cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Yoshihisa KodamaCenter of Interventional Radiology, Keiyukai Sapporo Hospital, Sapporo, Japan.
Masafumi IkedaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Yasuaki AraiGuest Researcher, National Cancer Center Hospital, Chūō, Japan.
Yoshitaka InabaDepartment of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Japan.
Toshihiro TanakaDepartment of Radiology, IVR Center, Nara Medical University, Kashihara, Japan.
Yasunori AraiDepartment of Diagnostic Radiology, National Cancer Center Hospital East, Kashiwa, Japan.
Shunsuke SugawaraDepartment of Diagnostic Radiology, National Cancer Center Hospital, Chūō, Japan.
Hajime YamazakiDepartment of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
Takeshi AramakiDivision of Interventional Radiology, Shizuoka Cancer Center, Shizuoka, Japan.
Hiroshi AnaiDepartment of Radiology, Nara City Hospital, Nara, Japan.
Shinichi MoritaDepartment of Gastroenterology and Hepatology, Uonuma Institute of Community Medicine, Niigata University, Hospital, Niigata, Japan.
Yasunari FujinagaDepartment of Radiology, Shinshu University School of Medicine, Matsumoto, Japan.
Hiroshi SekiDepartment of Diagnostic Radiology, Niigata Cancer Center Hospital, Niigata, Japan.
Mikio SatoDepartment of Gastroenterology and Hepatology, Ryugasaki Saiseikai Hospital, Ryugasaki, Japan.
Kenya KamimuraDivision of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
Junji ItoDepartment of Radiology, Ryukyu University Hospital, Nishihara, Japan.
Masakatsu TsurusakiDepartment of Radiology, Kindai University Faculty of Medicine, Osakasayama, Japan.
Tetsuro NakazawaDepartment of Diagnostic Imaging, Osaka General Medical Center, Osaka, Japan.
Hiroyuki TokueDepartment of Applied Medical Imaging, Gunma University Graduate School of Medicine, Maebashi, Japan.
Daisuke AboDepartment of Diagnostic and Interventional Radiology, Hokkaido University Hospital, Sapporo, Japan.
Kenichi KatoDepartment of Radiology, Iwate Medical University, Yahaba, Japan.
Natsuko HayashiDepartment of Radiology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Osamu SatoDepartment of Radiology, North Medical Center Kyoto Prefectural University of Medicine, Yosano, Japan.
Miyuki SoneDepartment of Diagnostic Radiology, National Cancer Center Hospital, Chūō, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Liver function deterioration after transarterial chemoembolization (TACE) may preclude systemic therapy. The JIVROSG-1302 PRESIDENT study, a prospective, randomized controlled trial, showed a significantly higher local complete response rate with selective conventional TACE (cTACE) than with selective TACE using drug-eluting beads (DEB-TACE). However, this study did not assess the changes in liver function after selective TACE. The purpose of this study, JIVROSG-2001 PRESIDENT-ALBI, was to evaluate the change in liver function after selective TACE for unresectable hepatocellular carcinoma (HCC) using the same patient cohort. Methods: The primary endpoint was ALBI grade deterioration rate after 3 months of TACE compared to DEB-TACE and cTACE. Secondary endpoints included the ALBI grade and score change and the identification of risk factors associated with liver function deterioration. Results: A total of 197 patients with unresectable HCC were enrolled in this study. The ALBI grade deterioration rate at 3 months was 11% for the DEB-TACE group and 6% for the cTACE group, with no significant difference ( Conclusions: Selective TACE, whether DEB-TACE or cTACE, did not significantly impair the liver function. Even with selective TACE, larger tumors, multiple tumors, and a large number of treated blood vessels were associated with worsening liver function 1 month after TACE.

Indexed as

ALBI gradeHepatocellular carcinomaLiver functionLiver functional reserveTransarterial chemoembolization

Identifiers

PMID41536555
PMCPMC12799235

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.